31 search results for: exacerbations

expert video

What is the Role of FeNO as an Asthma Biomarker?

2 min

Pulmonology

Prof. Klaus Rabe and Dr. Michael Wechsler explore the utility of FeNO as a biomarker in asthma.

expert video

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission

8 min

Pulmonology

Watch Prof G. Walter Canonica discuss the need to move beyond disease control to clinical remission in asthma and CRSwNP.

expert video

How Can FeNO Support the Management of Pediatric Asthma?

2 min

Pulmonology

Dr. Michael Blaiss discusses the importance of measuring FeNO in pediatric asthma patients.

videoanimation

Importance of Lung Function Assessment in Pediatric Asthma Patients

3 min

Pulmonology

Review the burden associated with lung function decline in pediatric patients with severe asthma, and the value of clinical lung function assessments.

expert video

Clinical Remission as a Goal in Asthma Clinical Practice

2 min

Pulmonology

Profs. Alberto Papi and Ian Pavord discuss clinical remission as a goal in asthma clinical practice beyond symptom control

interactivity

Why Is It Important to Assess Lung Function in Pediatric Asthma

5 min

Pulmonology

Learn about FEV1pp and the downstream effects of lung function decline in children with severe asthma

expert video

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

9 min

Rhinology

Prof. Peter Hellings discusses the interconnection between the pathophysiology, burden and clinical management of uncontrolled and/or severe CRSwNP

Infographic

Mucus Plugging Is a Key Component of Remodeling in Asthma, Leading to Fixed Airway Obstruction

3 min

Pulmonology

Learn about the role of type 2 inflammation in the burden and pathophysiology of mucus plugging in severe asthma

expert video

Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

19 min

Pulmonology

Dr. Leonard Bacharier discusses how type 2 inflammation underlies the pathophysiology of pediatric severe asthma and contributes to burden.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: IcelandChange country/region